Ewing Sarcoma - 30 Studies Found
| Terminated |
: Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma :
: 2012-05-31 : Drug: Mithramycin Phase I Portion: Mithramycin will be administered in escalating doses to children and |
| Completed |
: Genetic Biomarkers in Saliva Samples From Patients With Ewing Sarcoma : Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET) : 2013-06-10 :
|
| Completed |
: Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors :
|
| Completed |
: Study of Tumor Samples From Patients With Ewing Sarcoma : Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor : 2009-05-09 : Other: laboratory biomarker analysis Correlative studies |
| Completed |
: Osteosarcoma and Ewing Sarcoma Treatment Response Assessment With Functional MRI Imaging in Children and Young Adults :
: 2013-01-23 : Other: MRI MRI exam will be performed in all patients incl |
| Completed |
: Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma : Ewing Sarcoma : 2025-08-02 : Participants will receive cabozantinib in combination with high-dose ifosfamide for 5 cycles.If still on study therapy the participants will con |
| Completed |
: Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma : Refractory Ewing Sarcoma : 2025-08-02 : Administered as intravenous (IV) infusion once every 3 weeks (Q3W) |
| Completed |
: Lurbinectedin in FET-Fused Tumors : Ewing Sarcoma : 2025-08-02 : Lurbinectedin will be administered on a Day 1, Day 4 schedule every 21 days.Doses will be determined in the phase 1 portion of the trial. |
| COMPLETED |
: Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Will Change in Blood Loss and Transfusion Requirements. : Ewing Sarcoma of Bone : 2025-08-02 : . TXA, a lysine analogue, reversibly binds to the plasminogen lysine receptors and thereby blocks plasminogen from binding to fibrin (tPA can only act |
| COMPLETED |
: SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients : Ewing Sarcoma : 2025-08-02 : Patients with Ewing sarcoma will be administered trabectedin intravenously.Cycles are 21 days. |